Like this article? rabble is reader-supported journalism. Chip in to keep stories like these coming.
An American pharmaceutical corporation is suing Canadian taxpayers for $500 million.
Why? Because the Canadian government rejected their patent applications, thus making more affordable versions of their medication available.
However, the Trans-Pacific Partnership will extend patents, allowing corporations to keep drug prices higher for longer.
We need to make sure Canada does not pass the TPP through Parliament.
Thank you for reading this story...
More people are reading rabble.ca than ever and unlike many news organizations, we have never put up a paywall – at rabble we’ve always believed in making our reporting and analysis free to all. But media isn’t free to produce. rabble’s total budget is likely less than what big corporate media spend on photocopying (we kid you not!) and we do not have any major foundation, sponsor or angel investor. Our only supporters are people and organizations -- like you. This is why we need your help.
If everyone who visits rabble and likes it chipped in a couple of dollars per month, our future would be much more secure and we could do much more: like the things our readers tell us they want to see more of: more staff reporters and more work to complete the upgrade of our website.
We’re asking if you could make a donation, right now, to set rabble on solid footing in 2017.